Quick answer
Patient-derived tumor organoids need careful tissue handling, matrix culture, and cautious assay interpretation
A patient-derived organoid (PDO) is a three-dimensional culture established directly from a patient's tumor specimen. Unlike long-established cancer cell lines, tumor organoids can retain important genetic, phenotypic, and morphological characteristics of the original tumor.
PDO cultures are increasingly used for cancer biology, biomarker research, and preclinical drug-response testing. However, tumors are heterogeneous, and organoid establishment efficiency can vary substantially between patients, tumor types, and individual specimens.
Successful PDO culture therefore depends on rapid tissue processing, appropriate dissociation, selective growth conditions, and careful characterization before drug-screening results are interpreted.
Protocol boundary
Use this as general guidance
Cell-line-specific instructions, supplier recovery notes, institutional biosafety requirements, and your lab's validated SOP should take priority when they differ from this general workflow.
Workflow step
Step 1: Collect and Process Tumor Tissue
Obtain fresh tumor tissue under appropriate ethical, clinical, and biosafety procedures.
Transfer the specimen promptly into a suitable transport medium and process it as soon as practical. Delayed processing can reduce viable cell recovery.
Remove obvious necrotic material, blood clots, and non-tumor tissue when possible.
Using sterile instruments, mince the sample into small fragments. Pieces of approximately 1–2 mm provide a practical starting size for many dissociation workflows because smaller fragments increase the surface area available to digestion enzymes.
Avoid excessive crushing, which can rupture cells and release genomic DNA that increases sample viscosity.
Patient-derived material should always be handled according to institutional procedures for potentially infectious human specimens.
Workflow step
Step 2: Dissociate Tumor Cells
Digest the minced tumor using a tissue-specific enzymatic mixture.
Many solid tumor preparations use collagenase and hyaluronidase. Collagenase disrupts collagen-rich extracellular matrix, while hyaluronidase helps degrade hyaluronic-acid-containing stromal material.
Digestion is typically performed at approximately 37°C with gentle agitation. Because stromal density differs substantially among tumors, digestion duration should be optimized for the tissue rather than applied universally.
After enzymatic digestion, gently triturate the tissue to release cells and small epithelial clusters.
Pass the suspension through an appropriate cell strainer, commonly around 70 µm, to remove large undigested fragments.
Wash the recovered cells or clusters to remove residual digestive enzymes.
Some protocols favor small multicellular clusters rather than complete single-cell dissociation because excessive mechanical or enzymatic treatment can reduce organoid-forming efficiency.
Workflow step
Step 3: Embed in Matrix and Grow Organoids
Resuspend viable tumor cells or small tumor-cell clusters in a cold extracellular matrix hydrogel suitable for three-dimensional culture.
Dispense small matrix droplets or domes into a culture vessel and allow them to polymerize according to the validated procedure.
Once the matrix is stable, add a tumor-specific organoid culture medium containing the growth and niche factors required for the cancer type being studied.
Maintain the cultures at approximately 37°C under appropriate atmospheric conditions.
During the first several days, surviving cells may form small spherical or irregular structures. Over time, successful organoid-forming cells expand into larger three-dimensional colonies.
Avoid assuming that every structure is malignant. Normal epithelial cells can sometimes grow alongside tumor-derived organoids, depending on the tissue and medium.
Workflow step
Step 4: Expand Organoids for Drug Screening
Once established organoids become sufficiently dense, passage them into fresh matrix.
Organoids can be mechanically fragmented or dissociated according to the validated tumor-specific workflow. Avoid excessive dissociation unless single-cell passage has been shown to work reliably for that model.
For drug screening, expand cultures until enough organoids are available to distribute across replicate treatment conditions.
Standardize organoid size and seeding density as much as practical before drug exposure because large differences in starting biomass can affect measured responses.
Expose cultures to selected compounds over an experimentally appropriate concentration range and duration.
Drug sensitivity can be assessed using viability assays, metabolic readouts, imaging, apoptosis measurements, or other functional endpoints.
Patient-to-patient variability is expected. Two organoids originating from tumors with similar pathological classifications may respond differently because of distinct genetic and biological characteristics.
Expected Results
Expected Results
Successful cultures typically show the appearance of expanding 3D structures within several days to weeks after isolation.
Organoid morphology differs by tumor type and can range from compact spherical structures to irregular or glandular architectures.
After expansion, cultures should be capable of reproducible passaging while maintaining relevant tumor-associated features.
Before drug screening, confirm tumor identity using appropriate histological, molecular, or genomic methods.
Troubleshooting
Common problems to check
No Organoids Form
Low tumor-cell viability, excessive tissue digestion, inappropriate medium, or insufficient viable tumor content may be responsible.
Fibroblasts Overgrow the Culture
Stromal cells can proliferate rapidly. Tumor-specific selective conditions or differential handling may help, but any selection method can alter population composition.
Organoids Grow Slowly
Patient-derived cultures naturally vary in growth rate. Confirm culture conditions and avoid assuming slow growth indicates failure.
Drug-Screening Results Are Highly Variable
Standardize organoid number, size, treatment timing, and assay conditions. Biological heterogeneity between organoids may also contribute.
FAQ
Common questions
Do tumor organoids perfectly reproduce the original tumor?
No. They can retain important tumor characteristics but do not fully reproduce vasculature, immune components, or the complete tumor microenvironment.
Can every tumor establish an organoid culture?
No. Establishment efficiency varies substantially by tissue type and patient specimen.
Why use an ECM hydrogel?
The matrix provides structural and biochemical support that allows tumor-derived cells to grow as three-dimensional structures.
Can PDOs be used to predict patient drug response?
They can provide useful patient-specific experimental information, but clinical prediction requires disease-specific validation and should not be assumed from an experimental assay alone.
Products
Products used in this workflow
Cell culture dishes
Open-format culture, tissue handling, and microscopy workflows.
Shop cell culture dishes
